Pillstats
OTC · Solution/ Drops · Ophthalmic

Artificial Tears

Dextran 70 + Glycerin + Hypromelloses

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)4910
US makers1 labelers
Packages1
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.117$0.233$0.350$0.466Dec 2025Jan 2026Jan 2026
$0.404
Latest avg · Jan 21, 2026
-0%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

9061.8K2.7K3.6K2025 Q12025 Q22025 Q32025 Q42026 Q1
481
Rx · 2026 Q1
8.3K
Units dispensed
-85%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
AvPAKunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Apr 23, 2025
    RECALLRecall (Class II): Artificial Tears Ophthalmic Solution, Dextran 70.01%/Glycerin 0.2%/Hypromellose 0.3% (Eye Lubricants) Lubricant Eye Dro…

    cGMP deviations and lack of assurance of sterility. — Recalling firm: BRS Analytical Services, LLC — Nationwide in the USA